Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Sep 2019 to Sep 2024
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of
pharmaceutical industry solutions, today announced a strategic
relationship with Microsoft Corp. (NASDAQ: MSFT) aimed at developing new
Dendrite solutions on the Microsoft software platform.
Dendrite’s pharmaceutical expertise –
coupled with Microsoft’s technologies in
business intelligence (BI) and performance management –
will produce solutions to enable pharmaceutical companies to reach
prescribers and patients more effectively. Dendrite will develop its
solutions on a range of Microsoft products, including Microsoft SQL
Server 2005, Windows Vista and Windows Mobile.
As part of this relationship, Dendrite will also participate in Microsoft’s
Technology Adoption Program (TAP) which seeks to obtain real-world
customer feedback on Microsoft pre-release products. In turn, Microsoft
will work closely with Dendrite’s R&D efforts
to enable faster development cycles of life science-specific solutions
that give companies a competitive advantage.
“As the global pharmaceutical industry
continues to rapidly evolve, it creates a unique set of circumstances
that require companies to respond quickly, reliably and efficiently,”
said Subhash Vaid, Dendrite vice president of product marketing. “We’re
optimistic that Dendrite’s vast
pharmaceutical industry experience and Microsoft’s
strength in technology will lead to the creation of a whole new set of
rich solutions that will cater to these needs.”
“Pharmaceutical companies are faced with the
need to communicate directly to consumers as well as physicians in new
ways, while adding savings to the bottom line,”
said Paul Mattes, industry solutions director, U.S. Pharmaceutical and
Life Sciences Vertical Group, Microsoft. ”This
expanded relationship will allow companies to benefit from Dendrite’s
pharmaceutical expertise, while leveraging their existing IT investments
with Microsoft’s familiar and easy-to-use
technology.”
Dendrite’s strategic decision in July to make
its flagship sales force effectiveness solution Mobile IntelligenceTM
available on Microsoft SQL Server 2005 was a first step in the
relationship aimed at providing life science customers with additional
options that could result in a lower total cost of ownership. As a
result of this collaboration, the first application is expected to be
available during the first quarter of 2007 in the United States and
Japan.
About Dendrite
Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales,
marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company’s
clients are located in more than 50 countries and include the world's
top 20 pharmaceutical companies.
Note: Dendrite is a registered trademark of Dendrite International, Inc.
This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook," "guidance,"
and similar statements or variations. Such forward-looking statements
are based on our current expectations, estimates, assumptions and
projections and involve significant risks and uncertainties, including
risks which may result from our dependence on the pharmaceutical
industry; fluctuations in quarterly revenues due to lengthy sales and
implementation cycles for certain of our solutions; our fixed expenses
in relation to fluctuating revenues and variations in customers' budget
cycles; dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in the
economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological changes;
increased competition; international operations; integrating the
entities we acquire; our ability to effectively manage our growth; the
protection of our proprietary technology; our ability to compete in the
Internet-related products and services market; the continued demand for
Internet-related products and services; the ability of our third party
vendors to respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than anticipated
results from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect our
information technology infrastructure. Other important factors that
should be reviewed and carefully considered are included in the
company's 10-K, 10-Qs, and other reports filed with the SEC. Actual
results may differ materially. The company assumes no obligation for
updating any such forward-looking statements to reflect actual results,
changes in assumptions or other changes affecting such forward-looking
statements.
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of
pharmaceutical industry solutions, today announced a strategic
relationship with Microsoft Corp. (NASDAQ: MSFT) aimed at developing
new Dendrite solutions on the Microsoft software platform.
Dendrite's pharmaceutical expertise - coupled with Microsoft's
technologies in business intelligence (BI) and performance management
- will produce solutions to enable pharmaceutical companies to reach
prescribers and patients more effectively. Dendrite will develop its
solutions on a range of Microsoft products, including Microsoft SQL
Server 2005, Windows Vista and Windows Mobile.
As part of this relationship, Dendrite will also participate in
Microsoft's Technology Adoption Program (TAP) which seeks to obtain
real-world customer feedback on Microsoft pre-release products. In
turn, Microsoft will work closely with Dendrite's R&D efforts to
enable faster development cycles of life science-specific solutions
that give companies a competitive advantage.
"As the global pharmaceutical industry continues to rapidly
evolve, it creates a unique set of circumstances that require
companies to respond quickly, reliably and efficiently," said Subhash
Vaid, Dendrite vice president of product marketing. "We're optimistic
that Dendrite's vast pharmaceutical industry experience and
Microsoft's strength in technology will lead to the creation of a
whole new set of rich solutions that will cater to these needs."
"Pharmaceutical companies are faced with the need to communicate
directly to consumers as well as physicians in new ways, while adding
savings to the bottom line," said Paul Mattes, industry solutions
director, U.S. Pharmaceutical and Life Sciences Vertical Group,
Microsoft. "This expanded relationship will allow companies to benefit
from Dendrite's pharmaceutical expertise, while leveraging their
existing IT investments with Microsoft's familiar and easy-to-use
technology."
Dendrite's strategic decision in July to make its flagship sales
force effectiveness solution Mobile Intelligence(TM) available on
Microsoft SQL Server 2005 was a first step in the relationship aimed
at providing life science customers with additional options that could
result in a lower total cost of ownership. As a result of this
collaboration, the first application is expected to be available
during the first quarter of 2007 in the United States and Japan.
About Dendrite
Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies.
Note: Dendrite is a registered trademark of Dendrite
International, Inc.
This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.